Circassia Pharmaceuticals study data published in leading medical journal

03:31 EDT 8 May 2019 | Proactive Investors

The ASCENT phase IV study assessed the potential of the company's drug Tudorza to treat moderate-to-very severe chronic obstructive pulmonary disease

More From BioPortfolio on "Circassia Pharmaceuticals study data published in leading medical journal"